Eli Lilly Stock News

It doesn't seem like it based on the mercurial valuations of certain innovators but a rotation away from technology could open doors for stocks hedge funds are buying. Basically, it may be time to con

Some patients are willing to pay more for GLP-1 weight loss drugs like Wegovy than others — and it's strongly correlated to their annual income.

Eli Lilly's stock price has increased by 129% in a year, with a Forward Price-To-Earnings Ratio of 60.4. Lilly's valuation in a base case scenario at $171/share, considering traditional drug revenues.

Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite

Eli Lilly and Novo Nordisk are fierce competitors in the diabetes and obesity markets. Each company is investing heavily to scale up production to meet demand.

Eli Lilly's weight loss drugs are helping it conquer what may become a $100 billion market. Viking Therapeutics recently announced promising trial data for its weight loss candidate -- which works in

Older adults may now get Medicare coverage for the popular obesity drug Wegovy, so long as they're using it to cut their risk of serious heart problems and not for weight loss alone, according to new

By now, it's well established that Amazon (NASDAQ: AMZN ) is not only an e-commerce juggernaut and cloud-computing contender, but is also deeply involved in artificial intelligence technology. As Ama

Evan Seigerman, BMO Capital, joins 'Fast Money' to discuss BMO's inaugural GLP-1 conference.

Novo Nordisk's shares have benefited from some recent positive developments. The delay in the approval of donanemab has held back Eli Lilly's valuation.

Despite a few soft weeks, the stock market rally that began at the end of 2022 remains intact. We're now seeing signs that the rally is broadening out beyond the popular mega-cap technology stocks to

A new medical study is raising concerns over whether intermittent fasting, a weight-loss method that's gained attention in recent years, could pose heart-health risks.

Eli Lilly (LLY) closed the most recent trading day at $772.78, moving +1.33% from the previous trading session.

A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.